Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
NCT ID: NCT05833932
Last Updated: 2024-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2023-06-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke
NCT04950790
Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy
NCT05836753
Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
NCT03090113
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
NCT05700097
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
NCT06157502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Suhexiang Pill
Suhexiang Pill is an approved traditional Chinese patent medicine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18
* Patient who has received Suhexiang Pill treatment
* Patient or legally authorized representative has signed informed consent.
Exclusion Criteria
* Known to be pregnant or breastfeeding.
* With conditions that render outcomes or follow-up unlikely to be assessed.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dongzhimen Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ying Gao
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongzhimen Hospital
Beijing, Beijing Municipality, China
Dongzhimen Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lai X, Xiong X, Jia Q, Liu T, Yang Z, Zhang C, Kong L, Cao K, Dong T, Fang C, Ge J, Dong L, Zong Z, Chen S, Ma Y, Bai X, Wu D, Xie Y, Zhang M, Wang Y, Jiang G, Song D, Wang Y, Gui C, Geng Q, Gao Y; SUNRISE study investigators. Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry. BMC Complement Med Ther. 2025 Jan 28;25(1):30. doi: 10.1186/s12906-025-04762-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021XS-001-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.